| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
BASIC SCIENCE INVESTIGATIONS |
Divisions of Pediatric Radiology and Pediatric Hematology/Oncology, Lucile Salter Packard Children’s Hospital, Stanford; Division of Nuclear Medicine, Department of Radiology, Stanford, California; and Department of Laboratory Medicine, University of Washington, Seattle, Washington
Intramedullary apoptosis of hematopoietic tissue is believed to play a major role in the pathophysiology of myelodysplastic syndrome. Annexin V, a specific marker of the early to intermediate phases of apoptosis, has been applied to the in vitro study of bone marrow aspirates. A noninvasive measure of intramedullary apoptosis in vivo that could serially monitor the clinical progression of myelodysplastic syndrome may be helpful. Methods: We used 99mTc-radiolabeled annexin V and radionuclide gamma camera imaging to serially study the sites, extent, and severity of intramedullary apoptosis induced by cyclophosphamide treatment. Results: Intravenously administered radiolabeled annexin V localized preferentially in the femur, pelvis, vertebrae, and spleen; increased uptake in these organs was easily visualized as early as 8 h after injection of 100 mg/kg cyclophosphamide in 8- to 10-wk-old animals. Higher doses of cyclophosphamide (150 mg/kg) in animals of the same age increased annexin V uptake in the bone marrow and splenic tissue and delayed recovery of these organs as seen histologically compared with lower doses. Older animals, 5–6 mo old, showed a slower response to cyclophosphamide treatment and delayed recovery of bone marrow and splenic tissues. Conclusion: Radiolabeled annexin V can be used to detect and directly quantify the degree of intramedullary and splenic apoptosis in a noninvasive fashion using current clinical radionuclide imaging equipment. Annexin V imaging may be useful clinically in the diagnosis and management of myelodysplastic syndrome.
Key Words: annexin V • bone marrow • apoptosis • radionuclide
This article has been cited by other articles:
|
|
 |
|
  J. M H Van den Brande, T. C Koehler, Z. Zelinkova, R. J Bennink, A. A te Velde, F. J W ten Cate, S. J H van Deventer, M. P Peppelenbosch, and D. W Hommes Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease Gut, April 1, 2007; 56(4): 509 - 517. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Takei, Y. Kuge, S. Zhao, M. Sato, H. W. Strauss, F. G. Blankenberg, J. F. Tait, and N. Tamaki Enhanced Apoptotic Reaction Correlates with Suppressed Tumor Glucose Utilization After Cytotoxic Chemotherapy: Use of 99mTc-Annexin V, 18F-FDG, and Histologic Evaluation J. Nucl. Med., May 1, 2005; 46(5): 794 - 799. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Yagle, J. F. Eary, J. F. Tait, J. R. Grierson, J. M. Link, B. Lewellen, D. F. Gibson, and K. A. Krohn Evaluation of 18F-Annexin V as a PET Imaging Agent in an Animal Model of Apoptosis J. Nucl. Med., April 1, 2005; 46(4): 658 - 666. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Takei, Y. Kuge, S. Zhao, M. Sato, H. W. Strauss, F. G. Blankenberg, J. F. Tait, and N. Tamaki Time Course of Apoptotic Tumor Response After a Single Dose of Chemotherapy: Comparison with 99mTc-Annexin V Uptake and Histologic Findings in an Experimental Model J. Nucl. Med., December 1, 2004; 45(12): 2083 - 2087. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Taki, T. Higuchi, A. Kawashima, J. F. Tait, S. Kinuya, A. Muramori, I. Matsunari, K. Nakajima, N. Tonami, and H. W. Strauss Detection of Cardiomyocyte Death in a Rat Model of Ischemia and Reperfusion Using 99mTc-Labeled Annexin V J. Nucl. Med., September 1, 2004; 45(9): 1536 - 1541. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Ntziachristos, E. A. Schellenberger, J. Ripoll, D. Yessayan, E. Graves, A. Bogdanov Jr., L. Josephson, and R. Weissleder Visualization of antitumor treatment by means of fluorescence molecular tomography with an annexin V-Cy5.5 conjugate PNAS, August 17, 2004; 101(33): 12294 - 12299. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Peker, L. Sarda-Mantel, P. Loiseau, F. Rouzet, L. Nazneen, G. Martet, J.-M. Vrigneaud, A. Meulemans, G. Saumon, J.-B. Michel, et al. Imaging Apoptosis with 99mTc-Annexin-V in Experimental Subacute Myocarditis J. Nucl. Med., June 1, 2004; 45(6): 1081 - 1086. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Rohren, T. G. Turkington, and R. E. Coleman Clinical Applications of PET in Oncology Radiology, May 1, 2004; 231(2): 305 - 332. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Petrovsky, E. Schellenberger, L. Josephson, R. Weissleder, and A. Bogdanov Jr. Near-Infrared Fluorescent Imaging of Tumor Apoptosis Cancer Res., April 15, 2003; 63(8): 1936 - 1942. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Mochizuki, Y. Kuge, S. Zhao, E. Tsukamoto, M. Hosokawa, H. W. Strauss, F. G. Blankenberg, J. F. Tait, and N. Tamaki Detection of Apoptotic Tumor Response In Vivo After a Single Dose of Chemotherapy with 99mTc-Annexin V J. Nucl. Med., January 1, 2003; 44(1): 92 - 97. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. W. Vannier Imaging Apoptosis in Rheumatoid Arthritis J. Nucl. Med., October 1, 2002; 43(10): 1366 - 1367. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Belhocine, N. Steinmetz, R. Hustinx, P. Bartsch, G. Jerusalem, L. Seidel, P. Rigo, and A. Green Increased Uptake of the Apoptosis-imaging Agent 99mTc Recombinant Human Annexin V in Human Tumors after One Course of Chemotherapy as a Predictor of Tumor Response and Patient Prognosis Clin. Cancer Res., September 1, 2002; 8(9): 2766 - 2774. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
